文章摘要

文章信息/Info

Title:: Clinical experience of utilizing bioresorbable vascular scaffolds in the treatment of coronary bifurcation lesions

作者:: 赵瑞¹; 满万荣²; 顾菁³; 孙冬冬²; （1.兰州总医院心电图室，甘肃兰州730050;
第四军医大学：2.西京医院心血管内科，3.基础医学院外语教研室，陕西西安 710032）

Author(s):: ZHAO Rui¹; MAN Wan-rong²; GU Jing³; SUN Dong-dong²; (1.Department of Electrocardiogram, PLA Lanzhou General Hospital, Lanzhou 730050, Gansu, China;
2.Department of Cardiology, Xijing Hospital, 3.Department of Foreign Languages, Fourth Military Medical University, Xi’an 710032, Shaanxi, China)

关键词:: 冠状动脉分叉病变; 生物可吸收支架; 经皮冠状动脉介入治疗

Keywords:: coronary bifurcation lesions; bioresorbable vascular scaffold; percutaneous coronary intervention

分类号:: R618

DOI:: -

文献标识码:: A

摘要:: 生物可吸收支架的出现为冠状动脉分叉病变介入治疗提供了一种全新的策略。然而由于分叉病变的复杂性，在植入生物可吸收支架过程中还有多种技术手段可供选择。因此，本文旨在综合国外临床经验的基础上，对冠脉分叉病变应用生物可吸收支架策略选择做一综述。

Abstract:: Bioresorbable vascular scaffolds have been introduced as a novel strategy in treatment of coronary bifurcation lesions. Different strategies are employed to insert bioresorbable vascular scaffolds related to the complexity of bifurcation lesions. On the basis of clinical experience both at home and abroad, this manuscript reviews the choices of various strategies used to insert bioresorbable vascular scaffolds.

参考文献/References

[1]Lassen JF,Holm NR,Banning A,et al.Percutaneous coronary intervention for coronary bifurcation disease:11th consensus document from the European Bifurcation Club[J].EuroIntervention,2016,12(1):38-46.
[2]Diletti R,Garcia-Garcia HM,Bourantas CV,et al.Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial[J].Heart,2013,99(17):1267-1274.
[3]Serruys PW,Garcia-Garcia HM,Onuma Y.From metallic cages to transient bioresorbable scaffolds:change in paradigm of coronary revascularization in the upcoming decade?[J].Eur Heart J,2012,33(1):16-25.
[4]Farb A,Burke AP,Kolodgie FD,et al.Pathological mechanisms of fatal late coronary stent thrombosis in humans[J].Circulation,2003,108(14):1701-1706.
[5]Gogas BD,King SR,Samady H.Bioresorbable polymeric scaffolds for coronary revascularization:Lessons learnt from ABSORB III,ABSORB China,and ABSORB Japan[J].Glob Cardiol Sci Pract,2015,2015(5):62.
[6]Gao R,Yang Y,Han Y,et al.Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease:ABSORB China Trial[J].J Am Coll Cardiol,2015,66(21):2298-2309.
[7]Muramatsu T,Onuma Y,Garcia-Garcia HM,et al.Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold:an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials[J].JACC Cardiovasc Interv,2013,6(3):247-257.
[8]Dzavik V,Colombo A.The absorb bioresorbable vascular scaffold in coronary bifurcations:insights from bench testing[J].JACC Cardiovasc Interv,2014,7(1):81-88.
[9]纪兆乐，胡建华，杨亚丽，等.全吸收式血管支架的临床研究进展[J].心脏杂志,2016(6):727-730.
[10]Louvard Y,Thomas M,Dzavik V,et al.Classification of coronary artery bifurcation lesions and treatments:time for a consensus![J].Catheter Cardiovasc Interv,2008,71(2):175-183.
[11]Diletti R,Onuma Y,Farooq V,et al.6-month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mm[J].J Am Coll Cardiol,2011,58(3):258-264.
[12]Ormiston JA,Webber B,Ubod B,et al.Absorb everolimus-eluting bioresorbable scaffolds in coronary bifurcations:a bench study of deployment,side branch dilatation and post-dilatation strategies[J].EuroIntervention, 2015,10(10):1169-1177.
[13]Burzotta F,Trani C,Todaro D,et al.Prospective randomized comparison of sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach[J].JACC Cardiovasc Interv,2011,4(3):327-335.
[14]Kimura T,Kozuma K,Tanabe K,et al.A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs.everolimus-eluting metallic stents in patients with coronary artery disease:ABSORB Japan[J].Eur Heart J,2015,36(47):3332-3342.
[15]Huo Y,Finet G,Lefevre T,et al.Optimal diameter of diseased bifurcation segment: a practical rule for percutaneous coronary intervention[J].EuroIntervention,2012,7(11):1310-1316.
[16]Gomez-Lara J,Diletti R,Brugaletta S,et al.Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study[J].EuroIntervention,2012,8(2):214-224.
[17]Finet G,Gilard M,Perrenot B,et al.Fractal geometry of arterial coronary bifurcations:a quantitative coronary angiography and intravascular ultrasound analysis[J].EuroIntervention,2008,3(4):490-498.
[18]Hildick-Smith D,Lassen JF,Albiero R,et al.Consensus from the 5th European Bifurcation Club meeting[J].EuroIntervention,2010,6(1):34-38.
[19]van Geuns RJ,Gogas BD,Farooq V,et al.3-Dimensional reconstruction of a bifurcation lesion with double wire after implantation of a second generation everolimus-eluting bioresorbable vascular scaffold[J].Int J Cardiol,2011,153(2):e43-e45.
[20]Di Mario C,Foin N,Colombo A.Kissing vanishing stents: are we trading ephemeral benefit for permanent damage?[J].EuroIntervention,2013,9(7):777-779.
[21]Seth A,Sengottuvelu G,Ravisekar V.Salvage of side branch by provisional“TAP technique”using Absorb bioresorbable vascular scaffolds for bifurcation lesions:first case reports with technical considerations[J].Catheter Cardiovasc Interv,2014,84(1):55-61.
[22]Bourantas CV,Papafaklis MI,Kotsia A,et al.Effect of the endothelial shear stress patterns on neointimal proliferation following drug-eluting bioresorbable vascular scaffold implantation:an optical coherence tomography study[J].JACC Cardiovasc Interv,2014,7(3):315-324.
[23]Serruys PW,Onuma Y,Ormiston JA,et al.Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis:six-month clinical and imaging outcomes[J].Circulation,2010,122(22):2301-2312.
[24]Park DW,Park SW,Park KH,et al.Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up[J].Am J Cardiol,2006,98(3):352-356.
[25]Ruzsa Z,van der Linden M,Van Mieghem NM,et al.Culotte stenting with bioabsorbable everolimus-eluting stents[J].Int J Cardiol,2013,168(2):e35-e37.
[26]Lassen JF,Holm NR,Stankovic G,et al.Percutaneous coronary intervention for coronary bifurcation disease:consensus from the first 10 years of the European Bifurcation Club meetings[J].EuroIntervention,2014,10(5):545-560.
[27]van Mieghem N,Wilschut JJ,Ligthart J,et al.Modified T-technique with bioresorbable scaffolds ensures complete carina coverage:an optical coherence tomography study[J].JACC Cardiovasc Interv,2014,7(8):e109-e110.
[28]Colombo A.Contemporary treatment of coronary bifurcations with drug-eluting stent:part II[J].J Interv Cardiol,2006,19(1):51-53.
[29]Sharma SK,Choudhury A,Lee J,et al.Simultaneous kissing stents(SKS)technique for treating bifurcation lesions in medium-to-large size coronary arteries[J].Am J Cardiol,2004,94(7):913-917.
[30]Verheye S,Ormiston JA,Stewart J,et al.A next-generation bioresorbable coronary scaffold system:from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results[J].JACC Cardiovasc Interv,2014,7(1):89-99.
[31]Sato K,Latib A,Panoulas VF,et al.A case of true left main bifurcation treated with bioresorbable everolimus-eluting stent v-stenting[J].JACC Cardiovasc Interv,2014,7(8):e103-e104.
[32]Okamura T,Onuma Y,Garcia-Garcia HM,et al.3-Dimensional optical coherence tomography assessment of jailed side branches by bioresorbable vascular scaffolds:a proposal for classification[J].JACC Cardiovasc Interv,2010,3(8):836-844.

我们的网站为什么显示成这样？

生物可吸收支架在冠脉分叉病变中的应用经验

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

文章信息/Info

参考文献/References

备注/Memo

常用功能

导航/Navigate

工具/Tools

统计/Statistics